Can Dr Reddy’s shrug off Revlimid’s patent expiry?
DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
Zacks.com on MSN7h
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...
Opinion
Focus on new products at pharma companies as generic Revlimid opportunity draws to a close
Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...
The Desert Review1d
Ranking the Top 19 Terminal Cancer Repurposed Drugs
In this article, I employ AI to rank 19 repurposed drugs and supplements by effectiveness against metastatic cancer. To add ...
Dr Reddy’s share price jumps 4% on Nuvama’s upgrade to buy; brokerage sees potential despite risks from Revlimid expiry
Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...
Dr Reddy's shares rally 4% as Nuvama upgrades rating to buy
Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...
Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
ndtvprofit2d
Dr. Reddy's Gets 'Buy' Upgrade From Nuvama On Plans To Mitigate Key Patent Loss
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
ndtvprofit2d
Stock Recommendations Today: CarTrade Tech, Dr. Reddy's Labs, Doms Industries On Brokerages' Radar
B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...
Cure Today7d
CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in ...
Businessworld11d
online indian horse race betting
INR:4117. online indian horse race betting What is Sanofi’s new strategy after changing leadership, laying off employees, and adjusting pipelin ...
Businessworld11d
gym tshirt for men
INR:3848. gym tshirt for men BeiGene's REVLIMID Approved for Third Indication for the Treatment of Relapsed/Refractory Indolent Lymphoma c-Met inhibitors enter ...